Strides Pharma Science Ltd Technical Momentum Shifts Signal Mild Bullish Outlook

Technical Trend Shift and Price Movement

Strides Pharma Science Ltd (NSE: 688428) closed at ₹1,024.60 on 1 Sep 2026, marking a modest intraday gain of 0.40% from the previous close of ₹1,020.55. The stock traded within a range of ₹1,007.00 to ₹1,037.15, reflecting a degree of volatility but maintaining an upward bias. Over the past week, the stock has outperformed the Sensex, delivering a 3.10% return compared to the benchmark’s decline of 0.53%. This relative strength is notable given the broader market weakness.

Year-to-date, Strides Pharma has appreciated by 13.55%, significantly outperforming the Sensex’s negative return of 9.70%. Over longer horizons, the stock’s performance is even more impressive, with a three-year return of 405.93% versus the Sensex’s 18.70%, underscoring its strong growth trajectory within the pharmaceuticals and biotechnology sector.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator presents a nuanced picture. On a weekly timeframe, the MACD remains mildly bearish, suggesting some short-term caution. However, the monthly MACD has turned bullish, indicating that the longer-term momentum is improving. This divergence between weekly and monthly MACD readings suggests that while short-term traders may face some headwinds, the medium to long-term outlook is more favourable.

The Know Sure Thing (KST) indicator, which helps identify major price cycles, remains mildly bearish on both weekly and monthly charts. This signals that despite recent gains, the stock may still be consolidating before a more decisive uptrend emerges.

RSI and Overbought Conditions

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, hovering in neutral territory. This implies that the stock is neither overbought nor oversold, providing room for further price appreciation without immediate risk of a sharp correction. The absence of extreme RSI readings supports the view of a mild bullish trend rather than an overheated market condition.

Moving Averages and Bollinger Bands

Daily moving averages have turned mildly bullish, with the stock price trading above key short-term averages. This technical development often signals a positive shift in investor sentiment and can act as a support level in case of pullbacks. Meanwhile, Bollinger Bands show a mixed scenario: weekly bands are mildly bearish, indicating some price compression or volatility, whereas monthly bands are bullish, reinforcing the longer-term upward momentum.

Volume and Dow Theory Signals

On-Balance Volume (OBV) indicators on both weekly and monthly charts show no clear trend, suggesting that volume is not currently confirming or contradicting price movements. This lack of volume confirmation warrants caution, as price moves without volume support can be less sustainable.

Dow Theory assessments remain mildly bearish on both weekly and monthly timeframes, indicating that the broader market trend for Strides Pharma is still in a tentative phase. Investors should watch for confirmation of trend reversals before committing to aggressive positions.

Comparative Performance and Market Capitalisation

Strides Pharma is classified as a small-cap stock within the pharmaceuticals and biotechnology sector, carrying a MarketsMOJO Mojo Score of 67.0 and a Mojo Grade upgraded to 'Hold' from a previous 'Sell' as of 27 Jul 2026. This upgrade reflects improved technical and fundamental conditions, signalling a more balanced risk-reward profile for investors.

Despite its small-cap status, Strides Pharma’s long-term returns have been exceptional. Over five years, the stock has surged 264.76%, dwarfing the Sensex’s 33.72% gain. Even over a decade, the stock’s 154.14% return remains competitive, though slightly trailing the Sensex’s 170.48%. This performance highlights the company’s ability to generate substantial shareholder value over time, albeit with some volatility.

Key Technical Levels and Outlook

The stock’s 52-week high stands at ₹1,231.45, while the 52-week low is ₹769.60. Currently trading near ₹1,024.60, Strides Pharma is positioned roughly 17% below its annual peak, suggesting potential upside if bullish momentum sustains. However, the mixed technical signals advise investors to monitor key support levels around ₹1,000 and resistance near ₹1,050 to ₹1,070 for confirmation of trend continuation.

Given the mildly bullish daily moving averages and monthly MACD, the stock appears poised for gradual appreciation, provided broader market conditions remain stable. The neutral RSI and lack of volume confirmation imply that gains may be measured rather than explosive, favouring a cautious accumulation approach.

Investor Considerations and Sector Context

Strides Pharma operates in the pharmaceuticals and biotechnology sector, an area known for its growth potential but also regulatory and competitive risks. The company’s technical upgrade to a 'Hold' rating by MarketsMOJO reflects a stabilisation in price momentum and an improved risk profile. Investors should weigh these technical signals alongside fundamental factors such as earnings growth, pipeline developments, and sector dynamics.

While the stock’s recent outperformance relative to the Sensex is encouraging, the mildly bearish weekly MACD and KST indicators counsel prudence. A sustained break above the 52-week high could trigger stronger bullish momentum, but failure to hold current support levels may lead to renewed consolidation or correction.

Summary

In summary, Strides Pharma Science Ltd is exhibiting a cautiously optimistic technical outlook. The shift from a sideways to a mildly bullish trend, supported by daily moving averages and monthly MACD, suggests potential for further gains. However, mixed signals from weekly momentum indicators and volume trends advise measured exposure. The stock’s strong long-term returns and recent upgrade to a 'Hold' rating make it a noteworthy candidate for investors seeking exposure to the pharmaceuticals and biotechnology sector, albeit with an eye on key technical levels and broader market conditions.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →